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62 Poster Session-IThese data demonstrate that a combination of intrinsic and extrinsic
approaches can be used to shape a population of CAR1 T cells that
exhibit redirected specificity for CD19. Since the SB system has
achieved regulatory approval and the aAPC are being manufactured
to clinical grade through PACT/NHLBI, investigators are now
able to infuse cytolytic CD81 and CD41 T cells expressing markers
of central memory and ability to sustain proliferation.
Expression of CAR on CD81and CD41 T cells propagated on
aAPC with IL-2 1/- IL-21
Culture conditions CD41CAR1 CD81CAR1IL-2 42% 1%
IL-2 1 IL-21 22% 76%165
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Introduction: The tumor microenvironment is increasingly be-
ing recognized as a critical factor in mediating cancer development
and drug resistance. Despite a high response rate to chemotherapy,
the vast majority of patients with AML are destined to relapse due
to residual disease in the bone marrow (BM). We have previously
reported that AMD3100 (CXCR4 inhibitor) produces a rapid and
transient leukemia cell mobilization from BM into peripheral
blood, sensitizing leukemia cells to chemotherapy (ASH 2006,
Nervi et al).
Objectives:To evaluate the effect of the interaction between APL
and BM stroma in the expansion, survival and chemo/radio sensitiza-
tion of leukemia cells.
Results:We used amouse leukemia cell line generated by knock-
ing in the human PML-RARa cDNA (APL). To evaluate the phys-
ical interaction between APL cells and the bone marrow stromal
cells (BMSC), 5104 APL cells were cultured for 24h without or
with a BMSC monolayer (M2-10B4), or fibroblast monolayer (L-
cell). We observed 0%, 80% and 15% respectively (p\0.001). To
investigate the chemo/radio-sensitivity of APL cells, the latter
were cultured without and with BMSCs for 24h followed by the
addition of various increasing concentrations of AraC for 24h or ra-
diotherapy (xRt). Flow cytometric analysis of GR11 cells using ap-
optotic indicators such as Bcl-2, Annexin V and caspase-3 revealed
a significant protection from cell death of the APL cells by the BM
stroma. Furthermore, the analysis of the proliferative state of these
APL cells with or without stroma by flow cytometry using BrDU,
CFSE and PI showed a decreased cellular proliferation of APL cells
in the presence of BM stroma (7% proliferates with stroma versus
70% without stroma). N 5 24 mice were injected with 106 APL
cells iv and after 14 days the mice had an average of 10% APL cells
in the peripheral blood. Eight mice received 300cGy xRt in day 16,
and 8 mice received the combination of 300cGy 1 AMD3100 (1h
before and 3h later xRt to interrupt APL/stroma interaction). As
a control group 8 mice were left untreated. The mean survival for
the untreated, xRt, and xRt1AMDwere 21, 26 and 29 days respec-
tively (p\0,02).
Conclusion: BMmicroenvironment recruits APL cells to G0 and
increases antiapoptotic signals that protects leukemia cells from
apoptosis mediated by cytotoxic agents. The interruption of this
interaction may improve outcomes in leukemia therapy.166
OUTCOMES OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR PA-
TIENTS WITH ACUTE LEUKEMIA TRANSFORMED FROM MYELOFIBROSIS
Ciurea, S.O., de Lima, M., Giralt, S., Alousi, A., Kebriaei, P.,
Khouri, I.F., Anderlini, P., Andersson, B.S., Hosing, C.M.,
Champlin, R.E., Popat, U. University of Texas MD Anderson Cancer
Center, Houston, TXBackground and Rationale: Transformation of myelofibrosis
(MF) to acute leukemia (.20% blasts) portends a grave prognosis. Al-
logeneic stem cell transplantation (ASCT) is a curative approach for
patients with acute leukemia; however, the outcomes of ASCT in pa-
tients withMF transformed to acute leukemia are currently unknown.
Methods: Fifty-one consecutive patients with either primary
(PMF) or secondary (SMF) were transplanted at UTMDACC after
1994. Thirteen patients who developed AML (25%), 10 arising from
PMF and 3 with SMF, received an ASCT from a sibling or matched
unrelated donor. Median age was 59 years. Five patients (38%) had
prior splenectomy. JAK2V617F mutation analysis was performed in
7, and was present in 5 patients. Cytogenetics were intermediate in
10 and poor-risk in 3 patients. Seven patients (54%) were not in remis-
sion at the time of transplant. Eleven of 13 patients received induction
chemotherapy; 6 achieved remission, while 7 had persistent disease at
the time of transplant. One patient had a prior autologous transplant
and 2 patients had prior allogeneic transplant for myelofibrosis. The
donors were matched siblings (7 patients), matched unrelated (4 pa-
tients) and 1 antigen mismatched relatives (2 patients). The stem cell
source was peripheral blood in 9 and bone marrow in 4 patients.
Nine patients received a reduced-intensity conditioning regimen
with a fludrabine-melphalan-based regimen, and 4 myeloablative
conditioning (3 fludarabine-busulfan, 1 busulfan-cyclophosphamide).
Results: All patients engrafted, 75% achieved full donor chime-
rism, on day 30. Neutrophil and platelet engraftment occurred after
a median of 13 and 21.5 days. Twelve evaluable patients achieved re-
mission; 3 subsequently relapsed. JAK2V617F mutation became
negative after transplant in all tested patients and reappeared in 1 pa-
tient who later relapsed. Grade 2–4 aGVHD developed in 3 patients
(grade 3–4 in one) and cGVHD in 4/11 evaluable patients (extensive
in two). After a median follow-up of 17.2 months (range 7.2–128.6
mo), OS and EFS were 49% (SE 15%) and 44% (SE 14%), respec-
tively. Six patients died, related to disease relapse (2), pneumonia (2),
GVHD (1), and hepatic failure (1).
Conclusion: Patients with acute leukemia transformed from my-
elofibrosis with good performance status can achieve durable com-
plete remissions with ASCT.167
TOLERABILITY AND OUTCOMES OF A TARGETED INTRAVENOUS BUSUL-
FAN AND FLUDARABINE (T-BU/FLU) CONDITIONING REGIMEN FOR THE
TREATMENT DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA (AML)
Fernandez, H.F., Perkins, J., Field, T., Alsina, M., Ayala, E., Kharfan-
Dabaja,M., Ochoa, J.L., Perez, L., Raychaudhuri, J., Anasetti, C.Moffitt
Cancer Center, Tampa, FL
In an effort to reduce non-relapse mortality (NRM) and improve
survival in patients with AMLwe evaluated targeting busulfan to daily
AUCof 5300mmol/min/day. Since 2004we have treated 100 patients,
with de novo (66%) or secondary AML (34%), with a median age of 48
years (range 21–68)with a targeted IVbusulfan plus fludarabine (t-Bu/
Flu) reduced intensity regimen. 52 patients were in CR1, 23 in CR2
and 25 inadvanced AML. Of those in CR1, 50% had intermediate-
risk cytogenetics (IRC) and 50% had unfavorable-risk cytogenetics
(URC) at diagnosis. The patients were treated with t-BuFlu (Bu:
130–145 mg/m2/day on days 1 and 2 with pharmacokinetic targeting
for days 3 and 4; Flu 40mg/m2/day for 4 days). A median Bu AUC of
5265mmol/min/day was achieved. Patients received matched sibling
(38%), unrelated (40%), mismatched unrelated (21%) or mismatched
related (1%) HCT. GVHD prophylaxis consisted of tacrolimus plus
methotrexate or mycophenolate mofetil. Mismatched recipients re-
ceived rabbit ATG 7.5mg/kg as additional GVHD prophylaxis.
Results: NRM was 5% at 100 days and 17% at 1 year. Relapse
rates for patients in CR1 were 38.5 and 42.3 % (p 5 ns) for the
IRC and URC, respectively. With a median follow-up of 1 year,
EFS was 54% and OS was 57% at 1 year. There was a lower EFS
(63 vs. 30%, p 5 0.04) and a trend towards better OS (64 vs. 46%,
p5 0.07) for patient transplanted in CR1 compared to those beyond
first CR. There was no difference in the outcomes in EFS (p5 0.56)
or OS (p 5 0.98) between the IRC (n 5 56) and URC groups (n 5
40). Patients in first or second remission (n 5 74) had a better OS
(62 vs. 40%, p 5 0.04) than those not in remission (n 5 26) at the
time transplant. We noted a slight difference in outcomes based on
age below (n 5 66) or above (n 5 34) 55 years, but neither reached
statistical significance (EFS 58 vs. 44%, p 5 0.17; OS 60 vs. 49%,
